Inhibrx Biosciences Inc. (INBX)
NASDAQ: INBX
· Real-Time Price · USD
32.68
0.84 (2.62%)
At close: Sep 26, 2025, 3:59 PM
32.68
0.00%
After-hours: Sep 26, 2025, 07:22 PM EDT
Inhibrx Biosciences Revenue Breakdown
| Period Ending | Jun 30, 2025 | Dec 31, 2024 | Jun 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Sep 30, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License, Non-Affiliate Revenue | 1.3M | 100K | 100K | 1.75M | 119K | 30K | 17K | 278K | 711K | 915K | 2.51M | 918K | 863K | 3.83M |
| License, Non-Affiliate Revenue Growth | +1200.00% | 0.00% | -94.30% | +1373.11% | +296.67% | +76.47% | -93.88% | -60.90% | -22.30% | -63.52% | +173.20% | +6.37% | -77.44% | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 6.42M | 6.02M | 16.66M | 7.9M | 93.37M | 9.87M | 7.79M | 7.89M | 7.26M | 6.4M | 5.32M | 5.35M | 5.4M | 5.05M | 3.65M | 2.85M | 2.85M | 3.01M | 2.21M | 1.62M | 1.53M | 1.47M | 4.43M | 1.48M | 1.64M | 1.47M | 1.67M | 989K | 911K | 880K |
| Selling, General, and Administrative Revenue Growth | +6.61% | -63.84% | +110.79% | -91.53% | +845.96% | +26.77% | -1.31% | +8.62% | +13.54% | +20.18% | -0.45% | -1.02% | +6.95% | +38.57% | +27.98% | -0.18% | -5.18% | +35.85% | +36.56% | +5.87% | +4.43% | -66.91% | +199.39% | -9.47% | +11.52% | -12.21% | +68.96% | +8.56% | +3.52% | n/a |
| Research and Development Revenue | 22.27M | 36.88M | 33.37M | 38.89M | 67.63M | 63.59M | 81.84M | 38.06M | 34.11M | 37.39M | 30.45M | 24.93M | 29.91M | 24.89M | 18.61M | 18.48M | 17.9M | 16.44M | 17.67M | 19.84M | 18.97M | 17.02M | 12.28M | 12.79M | 12.17M | 10.66M | 4.68M | 8.49M | 10.78M | 7.29M |
| Research and Development Revenue Growth | -39.62% | +10.52% | -14.21% | -42.49% | +6.35% | -22.29% | +115.04% | +11.58% | -8.77% | +22.77% | +22.13% | -16.63% | +20.13% | +33.74% | +0.70% | +3.26% | +8.91% | -6.96% | -10.93% | +4.55% | +11.51% | +38.53% | -3.93% | +5.02% | +14.15% | +127.88% | -44.91% | -21.19% | +47.88% | n/a |